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Purpose: The aims of this study were to investigate the survival results and the prognostic factors of adjuvant chemother-
apy in stage II colon cancer in the sparsity of Korean data.
Methods: From 1993 to 2006, 363 curatively resected pathologic stage II colon cancer patients were enrolled. Six cycles of 
adjuvant chemotherapy was performed: intravenous bolus 5-fluorouracil (5-FU) 500 mg/m
2 with leucovorin 20 mg/m
2 for 
2 hours daily for 5 days, followed by a 3-week resting period (n = 308). Fifty-five patients received only curative surgery. A 
high risk of recurrence was defined as the presence of one or more of the following factors: T4 tumor, lympho-vascular in-
vasion, perineural invasion, perforation, obstruction, retrieved lymph node < 12, and poorly differention. The median fol-
low-up period was 68 months (1 to 205 months).
Results: The five-year overall survival (OS) rate was 90.1%, and the five-year disease-free survival (DFS) rate was 84.7%.   
Among high-risk patients, the OS and the DFS rates of the treatment group were significantly higher than those of the 
non-treatment group (OS: 90.6% vs. 69.1%, P < 0.0001; DFS: 85.9% vs. 54.1%, P < 0.0001). Among low-risk patients, the 
survival results of the treatment group were also significantly superior (OS: 97.7% vs. 88.2%, P < 0.0001; DFS: 93.0% vs. 
80.0%, P = 0.001). In the multivariate analysis, adjuvant chemotherapy was a significantly favorable prognostic factor for 
overall survival (hazard ratio, 0.41; 95% confidence interval, 0.22 to 0.75; P = 0.004).
Conclusion: In our population, adjuvant chemotherapy showed superior survival to curative surgery alone and signifi-
cantly reduced the risk of death. A nationwide multicenter randomized trial is needed.
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cancer is a curative resection, adjuvant chemotherapy following 
such curative resection has reduced the recurrence and mortality 
in locally advanced cases [2]. However, the benefit of adjuvant 
chemotherapy has been demonstrated usually for patients with 
lymph-node metastasis of stage III colon cancer. The benefits for 
patients wirh stage II colon cancer are still controversial. The IM-
PACT B2 study showed statistically insignificant effects of about 
2% in the treatment group when compared to the non-treatment 
group in stage II colon cancer, but the QUASAR study performed 
in 2007 showed a small, but statistically significant, difference of 
3.6% [3, 4]. 
As to the effectiveness of adjuvant chemotherapy in patients with 
stage II colon cancer, which has rarely been reported in Korea, the 
authors identified the effects of adjuvant chemotherapy using in-
travenous 5-fluorouracil (5-FU)/leucovorin (LV) in patients with 
stage II colon cancer who underwent a curative resection by com-
paring the survival rate with that of the non-treatment group. In 
addition, the prognostic effects of adjuvant chemotherapy for stage 
INTRODUCTION
Colorectal cancer is one of major cause of death in the west. How-
ever, according to 2008 statistics in Korea, the annual increase in 
the number of colon cancer cases has reached 5.3% and colon can-
cer is the third most common type of cancer [1]. 
Although the most important factor for the treatment of colon 
Received: August 30, 2011     Accepted: October 18, 2011
Correspondence to: Sun Mi Moon, M.D.
Department of Surgery, Korea Institute of Radiological & Medical Sciences, 
Korea Cancer Center Hospital, 215-4 Gongneung-dong, Nowon-gu, Seoul 
139-706, Korea
Tel: +82-2-970-1237, Fax: +82-2-970-2419 
Email: msm386@yahoo.co.kr
© 2011 The Korean Society of Coloproctology
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of The Korean Society of
Coloproctology
www.coloproctol.org 323
Volume 27, Number 6, 2011
J Korean Soc Coloproctol 2011;27(6):322-328
II colon cancer were investigated using a multivariate analysis.
METHODS 
Patients 
From 1993 to 2006, 363 colon adenocarcinoma patients who un-
derwent a curative resection and were diagnosed as having stage II 
colon cancer at the Korea Cancer Center Hospital were retrospec-
tively analyzed. The inclusion criteria was following. The distal part 
of the tumor was located 15 cm above the anal verge. Histologi-
cally, the tumor had invaded beyond the muscle layer to the se-
rosa or pericolic fat tissue, and no lymph node metastatis or sys-
temic metastasis was found. Rectal cancer and patients with a his-
tory of treatment for other cancer, metachronous colon cancer, 
recurring colorectal cancer and familial adenomatous polyposis 
or other hereditary colon cancer syndromes were excluded. 
The adjuvant chemotherapy was performed in patients aged over 
18 years with no history of receiving chemotherapy or radiation 
treatment and with proper hematological findings, hepatic and 
renal function after providing sufficient information on the pro-
cedure and obtaining their consents. 
Treatment 
The adjuvant chemotherapy was initiated at 3-8 weeks postopera-
tive. It was performed 6 times at 4-week intervals. The patient was 
treated by intravenous infusion of LV, 20 mg/m
2, with subsequent 
intravenous infusion of 5-FU, 500 mg/m
2, for 2 hours daily for 1 to 
5 days. 
Clinicopathological characteristics 
Gender, age, T stage in accordance with the Classification Version 
7 published by the American Joint Committee on Cancer (AJCC) 
[5], harvested lymph nodes, the grade of differentiation, the pres-
ence of lymphatic or vascular invasion, obstruction, perforation, 
recurrence and survival were investigated retrospectively. The high-
risk group of stage II colon cancer included patients with any of 
the following: T4 tumors, the presence of tumors with low histo-
logic grade, such as, poorly differentiated carcinomas, and undiffer-
entiated carcinomas; the presence of lymphatic, vascular or neural 
invasion; the presence of obstruction or perforation; or harvested 
lymph nodes less than 12. When patients had none of these risk 
factors, they were categorized as the low-risk group
Follow-up 
Patients were followed at 3-month intervals for 3 years postopera-
tive. During the 4th and the 5th year after surgery, they were ob-
served at 6-month intervals, and after the 5th year, they were ob-
served annually. Physical examination, serum carcinoembryonic 
antigen (CEA) level, carbohydrate antigen (CA) 19-9 level and 
chest X-ray were performed every time. Computerized tomogra-
phy of the thorax and abdomen was performed at 6-month to 1-year 
intervals. The median follow-up period was 68 months (1 to 205 
months).
Statistical analysis
The statistical analysis was performed using SPSS ver. 14.0 (SPSS 
Inc, Chicago, IL, USA). In the comparison among each variable, 
the Fisher’s exact test was used for nominal variables whereas the 
independent sample T test or the Mann-Whitney U test was used 
for continuous variables, depending on the presence of normality. 
As the method of survival analysis, the Kaplan-Meier’s method was 
used, and a log-rank analysis was performed for inter-group dif-
ferences. In order to identify the effects of adjuvant chemotherapy 
on the prognosis, the Cox-proportional hazard model was used 
for the univariate and the multivariate analyses. From the univari-
ate analysis, variables having significant values were selected; then, 
the multivariate analysis was performed on them. When the signif-
Table 1. Patients characteristics
Treatment  Non-treatment P-value
Number 308 55
Follow-up (mo) 68 (17-205) 62 (1-196)
Sex (male) 191 (62.0) 27 (49.1) 0.08
Age (median) 57 (25-81) 69 (31-86) <0.0001
Age ≥ 60 yr 132 (42.9) 44 (80) <0.0001
Tumor location
   Cecum 14 (4.5) 4 (7.3)
   Ascending colon  56 (18.2) 11 (20.0)
   Heptic flexure 30 (9.7) 3 (5.5)
   Transverse 22 (7.1) 10 (18.2)
   Splenic flexure 6 (1.9) 3 (5.5)
   Descending colon 14 (4.5) 2 (3.6)
   Sigmoid 113 (36.7) 15 (27.3)
   Recto-Sigmoid  53 (17.2)  7 (12.7)
Left sided 186 (60.4) 27 (49.1) 0.14
High risk of recurrence 213 (69.2) 38 (69.1) 1
   T stage
      T3 283 (91.9) 49 (89.1) 0.03
      T4a 14 (4.5)   0 (0)
      T4b 11 (3.6)  6 (10.9)
   Harvested LN < 12  71 (23.1)  8 (14.5) 0.21
   Lymphatic invasion 110 (35.7) 23 (41.8) 0.49
   Nerve invasion  48 (15.6) 4 (7.3) 0.14
   Vascular invasion 16 (5.2) 2 (3.6) 1
   PD/SRC/MUC 24 (7.8)  7 (12.7) 0.29
   Obstruction 26 (8.4)  8 (14.5) 0.2
   Perforation 2 (0.6)   1 (1.8) 0.39
Values are presented as number (%).
LN, lymph node; PD, poorly differentiated; SRC, signet ring cell; MUC, mucinous.Journal of The Korean Society of
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icance level was smaller than 0.05, it was considered as statistically 
significant. 
RESULTS
The median age of all patients was 59 years (range, 25 to 86 years) 
and the male was predominant gender. The treatment group, which 
received the intravenously infused 5-FU/LV, included 308 patients 
(84.8%). The non-treatment group, which received no adjuvant 
chemotherapy, included 55 patients (15.2%). Among the stage II 
colon cancer, 251 patients (69.1%) were in the high-risk group, 
and 112 patients (30.9%) were in the low-risk group. 
In the high-risk group, T4 tumors were present in 31 patients 
(8.6%), T4a in 14 patients (3.9%) and T4b in 17 patients (4.7%). 
Low histologic grade tumors, such as poorly differentiated carci-
nomas, undifferentiated carcinomas and mucous carcinoma were 
present in 31 patients (8.5%), lymphatic invasion in 133 patients 
(36.6%), vascular invasion in 18 patients (5.0%), neural invasion 
in 52 patients (14.2%), bowel obstruction in 34 patients (9.4%), 
and bowel perforation in 3 patients (0.8%). The number of resected 
lymph nodes was less than 12 in 79 patients (36.6%) (Table 1).
Recurrence occurred in 32 patients. The recurrence rate was 
higher in the high-risk group (26 patients, 10.4%) than in the low 
risk group (6 patients, 5.4%), but this difference had no statistical 
significance (P = 0.16). Among the 23 patients identified with re-
currence, hematogeneous metastasis (16 patients, 69.6%) was the 
most prevalent, followed by local recurrence (4 patients, 17.4%), 
distant lymph node metastasis (2 patients, 8.7%) and peritoneal 
metastasis (1 patient, 4.3%) in order. In hematogeneous metasta-
sis, hepatic metastasis was the most frequent (9 patients, 56.3%), 
followed by pulmonary metastasis (6 patients, 37.5%) and bone 
metastasis (1 patient, 6.3%)
The median period until recurrence was 23 months (range, 5 to 
11 months). Twenty-five patients died due to recurrences. The to-
tal number of deaths was 55.
Dependence of survival rate on adjuvant chemotherapy 
For all 365 patients, the 5-year disease-free survival rate (DFS) and 
the 5-year overall survival rate (OS) were 84.7% and 90.1%, respec-
tively. The 5-year OS of the treatment group was 92.8%, being sig-
nificantly higher than the 74.3% for the non-treatment group (P < 
0.0001). The 5-year DFS also showed a significant difference, being 
87.9% in the treatment group compared to 62.4% in the non-treat-
ment group (P < 0.0001).
In the 251 high-risk patients, the 5-year DFS and OS were 81.9% 
and 87.4%, respectively. The 5-year DFS and OS of the treatment 
group were 85.9% and 90.6%, respectively, as compared to 54.1% 
and 69.1% in the non-treatment group, differences that were sta-
tistically significant (P < 0.0001, P < 0.0001) (Fig. 1).
For the 112 low-risk group patients, the 5-year DFS and the 5-year 
OS were 91.2% and 96.2%, respectively. The 5-year DFS and the 5 
year OS of the treatment group were 93.0% and 97.7%, respectively, 
which were significant higher survival rates compared to the 80.0% 
and 88.2% for the non-treatment group (P = 0.001, P < 0.0001) 
(Fig. 2). 
Effects of adjuvant chemotherapy and prognostic factors for 
patients with stage II colon cancer 
In the univariate analysis, patient age ≥ 60 yrs (hazard ratio [HR], 
7.87; 95% confidence interval [CI], 3.83 to 16.15; P < 0.0001), T4 
tumor (HR, 2.21; 95% CI, 1.04 to 4.7; P = 0.04), vascular invasion 
(HR, 4.01; 95% CI, 1.56 to 10.26; P = 0.004), neural invasion (HR, 
2.14; 95% CI, 1.03 to 4.44; P = 0.04) and obstruction (HR, 3.52; 
95% CI, 1.85 to 6.72; P < 0.0001) were statistically significant fac-
tors that affected the overall survival as poor prognostic factors. 
Adjuvant chemotherapy reduced the risk of death with statistical 
significance (HR, 0.25; 95% CI, 0.15 to 0.43; P < 0.0001). 
In the multivariate analysis, patient age ≥ 60 (adjusted HR, 6.22; 
95% CI, 2.96 to 13.09; P < 0.0001), vascular invasion (adjusted HR, 
3.79; 95% CI, 1.33 to 10.8; P = 0.01) and obstruction (adjusted HR, 
2.29; 95% CI, 1.14 to 4.61; P = 0.02)  were independent risk factors 
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affecting the overall survival. In addition, adjuvant chemotherapy 
was independent favorable prognostic factor; the adjusted HR was 
0.41 (95% CI, 0.22 to 0.75; P = 0.004) (Table 2). 
DISCUSSION
Colon cancer is one of major cancers resulting in death worldwide. 
In Korea, it accounts for 12.7% of all cancers incidence, as a west-
ernized dietary has been rapidly spreading, and the number of new 
cases of colon cancer is showing a stiff increase [1]. Approximately 
in the past 10 years, the results of colon cancer treatment have im-
proved owing to early diagnosis, prevention and advancement of 
surgical techniques, but still about 1/3 of patients show recurrence 
of the disease. The most important factor for survival of patients 
with colon cancer is the radical surgery, and the survival period of 
patient is determined based on the postoperative pathological stage 
of the disease. 
Cases clearly showing the benefits of adjuvant chemotherapy are 
known to involve stage III colon cancer accompanied by lymph 
node metastasis, with a report on reduction in the risks of death 
and recurrence by 20-33% from 5-FU mono- or oxaliplatin com-
bined treatment [6, 7], allowing no objections on the effectiveness 
of adjuvant chemotherapy. However, in reality, still there is no con-
sistent consensus on whether adjuvant chemotherapy is required 
for patients with stage II colon cancer having no lymph node metas-
tasis and on what kind of chemotherapy regimen should be used. 
Except QUASAR trial presented in 2007 [4], most studies on adju-
vant 5-FU/LV treatment for stage II colon cancer could not iden-
tify the statistical superiority of adjuvant treatment over the cura-
tive surgery alone [3, 8-10], and such result is because of the diffi-
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Fig. 2. Kaplan-Meier survival curve in low-risk patients:  (A) overall survival and (B) disease-free survival.
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Table 2. Factors associated to overall survival in stage II colon cancer
Factor
Univariated Multivariated
HR 95% CI P-value HR 95% CI P-value
Male   1.03     0.6-1.76 0.92 1.18 0.67-2.08 0.58
Age ≥ 60   7.87     3.83-16.15  <0.0001 6.22   2.96-13.09  <0.0001
Left sided   0.81   0.47-1.38 0.43
T4   2.21 1.04-4.7 0.04 1.44 0.64-3.21 0.38
Harvested node < 12   1.15   0.61-2.14 0.67
PD/SRC/MUC   1.43   0.64-3.16 0.38
Lymphatic invasion   1.52   0.89-2.58 0.13
Vascular invasion   4.01     1.56-10.26   0.004 3.79 1.33-10.8 0.01
Neural invasion   2.14   1.03-4.44 0.04 1.59  0.7-3.57 0.27
Obstruction   3.52   1.85-6.72  <0.0001 2.29 1.14-4.61 0.02
Perforation 0.3   0.04-2.18 0.23
Chemotherapy   0.25   0.15-0.43  <0.0001 0.41 0.22-0.75   0.004
HR, hazard ratio; CI, confidence interval; PD, poorly differentiated; SRC, signet ring cell; MUC, mucinous.Journal of The Korean Society of
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culty in performing any large-scale clinical study to the extent nec-
essary to verify the superiority of the 5-FU/LV therapy. One study 
reported that in order to identify the significant difference made 
by adjuvant chemotherapy in patients with stage II colon cancer 
in a clinical study, more than 9,000 cases would be required [11]. 
For these reasons, many studies on adjuvant chemotherapy in pa-
tients with stage II colon cancer employed either pooled analysis 
or meta-analysis using existing studies.
This study aimed to identify the effects of 5-FU/LV adjuvant che-
motherapy without oxaliplatin in patients with pathologically 
proven stage II colon cancer. The results showed statistically sig-
nificant differences in survival rate for the group on whom adju-
vant chemotherapy in both the high- and low-risk subgroup. The 
results also showed that adjuvant chemotherapy was a significant 
prognosis factor affecting the overall survival. Although any direct 
comparison was difficult, when compared to an 83.7% 5-year DFS 
for patients with stage II colon cancer obtained from the MOSAIC 
trial using the FOLFOX4 regimen, the 5-year DFS of the our ad-
juvant chemotherapy group was 87.9%, which was either compar-
atively higher or similar. For the high-risk group, the 5-year DFS 
of our adjuvant treatment group was 85.9%, and when compared 
to the DFS of 82.3% obtained from the MOSAIC trial, the level of 
survival was similar. For now, it is quite difficult to identify clear 
reasons for these results. They could be due to differences in the 
doses of intravenously infused 5-FU (500 mg/m
2) at our institu-
tion, differences in the sensitivity, which depends on the race and 
differences in the developmental gene expression of the tumor; 
nonetheless, above all, it is most likely the result of treatment per-
formed by experienced colon cancer specialists at a single center 
above all. 
According to studies being presented in recent days, the perfor-
mance of postoperative adjuvant chemotherapy and its regimens 
for stage II colon cancer are recommended differently depending 
on whether the patients have the high-risk features for recurrence. 
In the MOSAIC study, the FOLFOX therapy, which was used for 
all patients with stage II colon cancer, did not show significant bet-
ter results compared to monotherapy of 5-FU in terms of overall 
survival rate or disease-free survival rate. However, in stage II cases 
with T4 tumors, bowel obstruction, poor differentiation, vascular 
invasion or with the number of retrieved lymph nodes less than 
10, considering them as the high-risk group for recurrence, the 
FOLFOX therapy showed that survival tended to improve, and 
the 6-year follow-up observation reported the same result (HR for 
DFS, 0.76; 95% CI, 0.49 to 1.06) [12]. On the contrary, the benefits 
of FOLFOX therapy were not identifiable in the group with no risk 
factors for recurrence. Based on these study results, FOLFOX ther-
apy had been recommended for high-risk patients with stage II 
cancer, and in 2006, the use of oxaliplatin was approved in high-
risk patients with stage II cancer risk in Korea. However, from the 
NSABP C-07 study conducted under similar design, the benefits 
of FOLFOX therapy were identified only in stage III colon cancer 
[13], and also according to a report based on pooled analysis from 
NSABP C-05, C-06, C-07, and C-08 at the annual meeting of the 
2011 American Society of Clinical Oncology (ASCO), an investi-
gation on the treatment result of FOLFOX therapy in 991 patients 
with stage II colon cancer found only insignificant differences of 
2-3% from both the high- and low-risk group, where patients with 
intestinal perforation or T4 stage of disease and with the number 
of harvested lymph nodes less than 12 were defined as the high-risk 
group; the investigation also found that the therapy was seemingly 
not so effective as to warrant risking further danger such as long-
term neurotoxicity [14]. Therefore, even though our study subjects 
were a group of patients retrospectively recruited by a single cen-
ter, in consideration of the facts that the 5-FU treatment group had 
shown better survival result than the FOLFOX treatment group of 
the MOSAIC study, or that the cancer treatment results of Korea had 
shown a higher than those of the western countries [15], further 
studies will be required on how much more beneficial FOLFOX 
therapy would be as it expresses a far higher frequency of toxic reac-
tion including neurotoxicity, compared to 5-FU/LV therapy in pa-
tients with stage II colon cancer and on which patient group should 
be subjected to such benefits if it would be beneficial at all [16].
In fact, according to the disease stage classification currently in 
use [5], stage II colon cancer is simply defined as cases in which a 
tumor with no lymph node metastasis has invaded beyond the 
proper muscle of the colon. However, such a definition includes a 
quite diversified wide range of tumors from tumors with no other 
specific risk factors to tumors that aggressively invade surround-
ing organs and show findings of a wide range of vascular invasion. 
To this end, some tumors show prognosis that are consistent with 
or even worse than that of stage III cancer in terms of recurrence 
in spite of no lymph node metastasis [17, 18]. Thus, investigations 
have been implemented on various clinical and pathological risk 
factors for recurrence in order to identify the high-risk group for 
such recurrence and to identify the target group that would bene-
fit from adjuvant chemotherapy. So far, the risk factors universally 
accepted are emergency surgery under the conditions of cancer 
perforation or obstruction, low histological grade of tumor and 
the invasion to other organs, and perivascular, perilymphatic and 
perineural invasions [19-22]. In addition, patients with conditions 
that cannot be considered as stage II cancer, i.e., with the number 
of retrieved or investigated lymph nodes less than 10 to 12, are also 
included [23]. In this study, on the univariate analysis, patients with 
T4 tumors (stage IIB/C) showed significantly poor prognosis com-
pared to patients with T3 tumors (stage IIA); the multivariate anal-
ysis also showed a poor prognosis even though this result was not 
statistically significant. However, although it was not described 
earlier, we could not find any tendency of T4b tumors showing a 
poorer prognosis than T4a tumors in our population, which was 
shown in the Surveillance, Epidemiology and End Results (SEER) 
Report [17]. Additionally, as in existing studies, vascular and neu-
ral invasions or bowel obstruction were significant risk factors in 
this study, and also tumors with lymphatic invasion, the number of 
obtained lymph nodes less than 12 and poor differentiation showed Journal of The Korean Society of
Coloproctology
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a tendency to have a poor prognosis, but this result was statistically 
insignificant. 
Determination of risk factors based on such clinical, pathologi-
cal factors could be quite subjective and could be produce diversi-
fied results depending on the reporters, so a need to develop more 
objective and reproducible risk factors has emerged, and various 
molecular biomarkers have been studied accordingly. Among them, 
the most representative one is the presence of a microsatellite in-
stability (MSI), and in this case, adjuvant chemotherapy is not rec-
ommended because the MSI-high (H) group presents a good prog-
nosis in the absence of any other risk factors [23]. To this end, some 
researchers classify cases of any MSI status with the aforementioned 
clinical and pathological risk factors as the high-risk group, while 
classifying cases of MS stable (S) with no risk factors as the aver-
age risk group and cases of MSI-H with no risk factors as low risk 
group [24]. Along with them, 18q loss of heterozygosity (LOH) [25] 
and mutation of KRAS, BRAF genes [26] are being studied as risk 
factors, but in this study, analyses of such molecular biomarkers 
were not performed due to the limits of a retrospective study, so 
such analyses will be performed in future. 
This study has limits as a retrospective study in that the factors 
likely to affect survival, such as the age and the T4b, which showed 
poor survival results in the SEER Report [17], were not evenly dis-
tributed between the treatment and control group. Also, there are 
limits in accepting the results of this study as the number of pa-
tients in the non-treatment group was much lower than the num-
ber in the treatment group as most patients with stage II colon 
cancer received adjuvant chemotherapy according to our hospital 
policy. Nonetheless, the results of this study seem to have value as 
domestic data because there have been few reports on the effec-
tiveness of adjuvant chemotherapy only in patients with stage II 
colon cancer in Korea so far [27, 28]. 
In this study, the 5-year disease-free survival rate and the 5-year 
overall survival rate of patients with stage II colon cancer after ad-
juvant chemotherapy were 87.9% and 92.8%, respectively. This re-
sult was found to be statistically significant for both the high- and 
the low-risk group in comparison to the surgery-only group. In the 
multivariate analysis, adjuvant chemotherapy was found to be in-
dependent prognostic factor that affected overall survival. In the 
future, prospective multicenter studies addressing the cost benefit 
of, the risk benefit of, and the choice of an appropriate adjuvant 
chemotherapy regimen in the treatment of stage II colon cancer 
patients will be required.  
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